Global Laboratory Informatics Market Outlook, 2031

Laboratory informatics is the set of software systems that capture, manage, analyse and report the data produced in scientific and clinical laboratories. The core products are laboratory information management systems, which track samples, tests, results, workflows, instruments, inventory and certificates of analysis; electronic laboratory notebooks, which record experiments and intellectual property in research settings; scientific data management systems, which archive raw and processed instrument data; laboratory execution systems, which guide analysts through procedures; and chromatography data systems, which control instruments and process results. In clinical settings, laboratory information systems manage patient specimens, orders and reporting and connect to hospital records, a segment that overlaps with this market. Suppliers include Thermo Fisher Scientific with SampleManager and Chromeleon, LabWare, LabVantage, STARLIMS, Waters, Agilent, Dotmatics, Benchling, IDBS, Clinisys and Sunquest, with newer cloud-based platforms from Sapio Sciences, Genedata and others. Systems are sold as licences with annual maintenance, as subscriptions in the cloud, or as configured projects delivered by consultancies, and implementations often take many months because of instrument integration, workflow design and validation. Customers include pharmaceutical and biotechnology companies, contract research and manufacturing organisations, clinical and public health laboratories, food and beverage testers, environmental labs, chemical and energy companies, and academic institutions. Laboratory informatics is used to meet quality and data integrity rules such as good laboratory practice, good manufacturing practice, 21 CFR Part 11, EU Annex 11, ISO/IEC 17025 and ISO 15189. The market now sits at an inflection point shaped by cloud adoption, platform consolidation and artificial intelligence. Pharmaceutical and biotechnology companies are replacing patchworks of legacy LIMS, notebooks and spreadsheets with unified platforms that link research, development and quality control data, and software providers are consolidating to offer broader suites, as with Siemens' agreement to acquire Dotmatics in 2025. Cloud-native tools designed for modern biology, such as Benchling, have shifted expectations for user interfaces and integration, and large vendors are responding with SaaS versions of established products. Data integrity expectations are rising, with the European Union consulting in 2025 on a revised Annex 11 and a new annex on artificial intelligence in manufacturing, and the United States seeing changes in the regulation of laboratory-developed tests. Generative AI assistants, instrument integration standards and robotic automation are pushing laboratories toward connected, data-rich operations. For researchers, the key variables through 2031 are the speed of SaaS migration, regulatory requirements for data integrity and AI, consolidation among vendors, integration with instruments and automation, demand from biologics and cell and gene therapy, and public and private funding for testing capacity. Drivers •Regulatory Pressure on Data Integrity and Quality: Regulators expect laboratories to maintain complete, consistent and accurate records, following the ALCOA principles of attributable, legible, contemporaneous, original and accurate data, and inspection findings on data integrity are common in pharmaceutical and clinical testing. Informatics systems enforce audit trails, electronic signatures, access control and controlled workflows, reducing manual transcription and spreadsheet use. The Food and Drug Administration finalised guidance on data integrity in 2018, ISPE published a second edition of the GAMP 5 guide in 2022, and revisions to EU rules are under discussion, so spending on compliant systems is closely tied to regulatory activity. •R&D Complexity, Biologics and Testing Volume: Drug discovery and development generate growing volumes of data from sequencing, mass spectrometry, high-content imaging and bioassays, and biologics, cell and gene therapies and vaccines need extensive characterisation and release testing. Contract research and manufacturing organisations scale quickly and need standard systems across sites. Clinical laboratories handle more molecular and genomic tests, and environmental, food and forensic labs process large sample counts. These trends raise demand for systems that manage samples, workflows and results at scale and link laboratories with manufacturing and clinical records. Challenges •Implementation Cost, Integration and Legacy Systems: Projects can take a year or more and require process redesign, interface development with instruments and enterprise systems, and extensive validation, so costs are high and failed implementations are a known risk. Many laboratories use customised legacy LIMS that are hard to upgrade, and instrument vendors use proprietary formats that complicate integration. Data remains in silos between research, quality and manufacturing, limiting analytics. Customers need skilled staff to configure and maintain systems, and shortages of laboratory informatics specialists slow progress. •Validation Burden, Cybersecurity and Vendor Dependence: Regulated laboratories must validate software and manage change control, and cloud and SaaS models raise questions about supplier audits, data location and release cycles. Laboratories hold intellectual property and patient data, making them targets for cyberattack, and operational disruption can halt testing. Consolidation among vendors may reduce choice and increase pricing power, while customers worry about lock-in and the cost of migrating years of data. Clear exit terms, open data formats and strong supplier oversight become part of buying decisions. Trends •SaaS Platforms and Unified Data Models: Vendors and customers are moving to cloud-based, multi-tenant platforms that combine notebook, sample management, inventory, assay data and workflow tools on a common data model, so that scientists can search and analyse across projects. Benchling, Dotmatics, Sapio, IDBS and Thermo Fisher offer such platforms, and traditional LIMS vendors are releasing cloud versions. Customers value rapid deployment, regular updates and APIs, and use them to connect to data lakes and analytics tools. Standard data models, such as the Allotrope framework and FAIR data principles, are gaining support because they make data easier to reuse. •Lab Automation, Instrument Connectivity and Generative AI: Robotic liquid handlers, automated storage and high-throughput screening systems are being linked to informatics through standards such as SiLA 2 and OPC UA, creating closed loops between experiment design, execution and analysis. Generative AI is being added to notebooks and LIMS to summarise results, search protocols, draft reports and suggest experiments, and machine learning models help predict assay outcomes and detect anomalies in quality testing. Vendors stress governed AI that respects audit trails, and regulators are developing expectations for validation. These developments move laboratories toward self-driving and remote operation. Laboratory information management systems lead by revenue because they are the backbone for sample and test management in quality control, clinical and testing labs, while electronic laboratory notebooks and scientific data platforms are growing quickly in discovery and development settings. LIMS manages sample login, test assignment, instrument interfaces, results review, specification checks and reporting, and can be configured for pharmaceutical quality control, food safety, environmental analysis or clinical research. Electronic laboratory notebooks replace paper in research, capturing protocols, observations and files, and increasingly combine with inventory and assay tools. Scientific data management systems archive raw data and metadata from instruments and enforce retention rules, while laboratory execution systems guide analysts and reduce errors in regulated testing. Chromatography data systems, from Thermo Fisher, Waters and Agilent, control chromatographs and process results, and are central in pharmaceutical analysis. Other software includes inventory management, analytics, workflow orchestration and laboratory information systems for clinical settings. Innovation through 2031 is focused on converged platforms, cloud delivery and low-code configuration. On-premises deployments lead the installed base because regulated laboratories validated systems over many years and are cautious about change, while cloud and SaaS deployments are the fastest-growing mode as vendors offer validated cloud services and customers want faster deployment and lower infrastructure cost. On-premises LIMS and notebooks run on servers inside the customer's network, giving control over upgrades and integration with local instruments, but require hardware, database administration and periodic upgrades that can be disruptive. Cloud and SaaS offerings are hosted by the vendor or a public cloud, with subscription pricing and frequent releases, and vendors provide validation packages that reduce customer burden. Hybrid models keep instrument integration or sensitive data on site while using cloud analytics and collaboration. Migration from on-premises to cloud is often tied to platform replacement projects, and large pharmaceutical firms are moving in phases. Data residency rules and customer preference for private cloud affect choices. Through 2031, cloud is expected to take most new deployments, while on-premises systems will persist in conservative sectors. Software leads by revenue because licences and subscriptions form the base of the market, while services, including implementation, validation, integration, training and managed operation, represent a large and growing share because of project complexity. Software revenue includes licences, subscriptions and maintenance for LIMS, notebooks, data management and related tools, with large vendors offering module-based pricing and cloud customers paying per user or per site. Services include configuration of workflows, development of instrument interfaces, migration of historical data, computer system validation, training and support, and are delivered by vendors and by consultancies and integrators. Managed services, in which a provider operates the system and handles upgrades, are rising as customers seek to reduce internal burden. Instrument vendors bundle data systems with hardware and services, adding to switching costs. Pricing pressure from cloud entrants and from open-source or low-code tools is pushing vendors to show value through speed of deployment and scientific functionality. Through 2031, outcome-based and usage-based pricing is expected to become more common. Pharmaceutical and biotechnology companies lead as end users because they have large, regulated and data-intensive laboratories, while contract research and manufacturing organisations, clinical and diagnostic laboratories and food, environmental and chemical testing labs are important and growing groups. Pharmaceutical and biotechnology firms use laboratory informatics across discovery, preclinical, clinical, development and quality control, and typically operate multiple systems that they seek to integrate. Contract research and manufacturing organisations, including those serving biologics and cell and gene therapy developers, need systems that can be configured per client and meet inspection standards. Clinical, hospital and public health laboratories use laboratory information systems and increasingly genomic and molecular workflows, and are affected by regulation of laboratory-developed tests. Food, beverage, environmental, forensic, petrochemical and agricultural laboratories use LIMS for accreditation to ISO 17025, with demand supported by safety rules and sustainability reporting. Academic and government research institutions use notebooks and data platforms, often with open-source tools. Through 2031, growth is expected across all groups, led by biopharma and contract organisations. The United States is the largest market, with major pharmaceutical clusters in Boston, San Francisco, New Jersey and North Carolina, and a deep base of biotechnology and clinical laboratories. Regulation by the Food and Drug Administration, the Clinical Laboratory Improvement Amendments and state authorities shape system design, and companies such as Thermo Fisher Scientific, Waters, Agilent, LabWare, LabVantage, Benchling and Dotmatics compete. The FDA's final rule on laboratory-developed tests in May 2024 was set aside by a federal court in March 2025, leaving the regulatory path for these tests unsettled. Siemens' agreement in April 2025 to acquire Dotmatics showed strategic interest in R&D software. Canada has a smaller biotechnology sector with provincial laboratory networks, and Mexico's contract manufacturing and diagnostics sectors are growing with international vendors. Europe has a strong pharmaceutical and chemical base, with Switzerland, Germany, the United Kingdom, France, Belgium, Denmark and Ireland as major centres. EU GMP Annex 11 and the Medicines and Healthcare products Regulatory Agency's data integrity expectations influence system selection, and a draft revision of Annex 11 and a new Annex 22 on artificial intelligence were released for consultation in 2025. The In Vitro Diagnostic Regulation, applicable from May 2022 with transition periods, increases requirements on diagnostic laboratories and manufacturers. Vendors include LabWare, LabVantage, Clinisys, Siemens, Dassault Systemes and Thermo Fisher, and public health laboratories and national genomic programmes are major buyers. Data protection under GDPR affects clinical data. Cloud adoption is growing but with attention to sovereignty and validation. Asia-Pacific is the fastest-growing region, driven by contract research and manufacturing organisations, generic drug production and expanding clinical testing. China has large CRO and CDMO companies, a growing biotechnology sector and strong domestic software providers, and the National Medical Products Administration is raising data integrity expectations. India is a leading generic drug producer with many facilities inspected by international regulators, which has encouraged investment in LIMS and data integrity tools, and its diagnostics sector is expanding. Japan has a mature market with strong life science and food testing sectors, and the regulator PMDA issues guidance on electronic records. South Korea has a growing biopharma and biologics manufacturing sector, Singapore is a regional hub for research and manufacturing, and Australia has a research-intensive market with public health laboratories. Latin America has a smaller but developing market, led by Brazil and Mexico. Brazil's ANVISA regulates pharmaceutical quality and laboratory practices, and large private laboratory groups such as Dasa and Fleury use laboratory information systems at scale, while public health laboratories support national programmes. Mexico's pharmaceutical and medical device manufacturing sector and its public laboratories adopt LIMS, often through regional integrators. Argentina, Chile and Colombia have growing clinical and environmental testing sectors, and mining and agriculture create demand for analytical labs. Budget limits and currency volatility slow investment, so cloud and subscription pricing are attractive. Adoption of international accreditation standards is a driver, particularly for export-oriented food and agricultural testing, and is expected to support growth through 2031. The Gulf has the most active market in the region, with investment in genomics, clinical laboratories and pharmaceutical manufacturing under national strategies in Saudi Arabia, the United Arab Emirates and Qatar. The Saudi Food and Drug Authority and the Emirates Drug Establishment set quality and data requirements, and large laboratory networks and national genome programmes buy modern systems. Israel has a strong biotechnology sector with advanced digital adoption. In Africa, South Africa has the most developed laboratory market, while national public health laboratories in countries such as Nigeria, Kenya and Rwanda have strengthened systems with support from global health funders after the pandemic. Infrastructure and skills constraints limit adoption, though cloud solutions and regional accreditation efforts are expected to expand use through 2031. July 2025: EU consults on revised Annex 11 and new Annex 22: The European Commission and inspection bodies published drafts updating rules for computerised systems and addressing artificial intelligence in manufacturing, signalling tighter expectations for data integrity, validation and supplier oversight. April 2025: Siemens agrees to acquire Dotmatics: The planned acquisition of the scientific R&D software provider brought a major industrial software company into laboratory informatics and pointed to consolidation among research and quality platforms. March 2025: Federal court sets aside FDA rule on laboratory-developed tests: A US district court vacated the agency's rule, which would have regulated certain laboratory tests as medical devices, leaving oversight under existing laboratory regulations and affecting compliance planning for clinical labs. May 2024: FDA issues final rule on laboratory-developed tests: The rule set a phased approach to regulate such tests as devices, prompting laboratories and software providers to prepare for quality system and reporting requirements before it was later vacated. July 2022: ISPE publishes second edition of GAMP 5: The updated guide for compliant computerised systems emphasised risk-based validation, critical thinking and agile and cloud approaches, influencing how laboratories validate informatics platforms. Considered in this report • Historic Year: 2020 • Base Year: 2025 • Estimated Year: 2026 • Forecast Year: 2031 Aspects covered in this report • Global Laboratory Informatics Market with its segments and regional outlook • Various drivers and challenges • Ongoing trends and developments • Key developments and regulatory milestones By Product Type • Laboratory Information Management Systems • Electronic Laboratory Notebooks • Scientific Data Management Systems • Laboratory Execution Systems • Chromatography Data Systems and Others By Deployment Mode • On-Premises • Cloud-Based and SaaS • Hybrid By Component • Software • Services By End User • Pharmaceutical and Biotechnology Companies • Contract Research and Manufacturing Organisations • Clinical and Diagnostic Laboratories • Food, Environmental and Chemical Testing Laboratories • Academic and Research Institutions

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Sikandar Kesari

Research Analyst

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now